New COVID Pill Offers Post-Exposure Protection

The Food and Drug Administration has approved Xocova, a new medication designed to prevent COVID-19 following direct exposure to the virus. This pill is available for individuals aged 12 and older who have had close contact with someone who has tested positive.

Studies indicate that taking Xocova within three days of exposure can significantly decrease the likelihood of contracting COVID-19 by as much as two-thirds. Even if an infection occurs, the illness appears to be less severe and shorter in duration.

This post-exposure treatment is intended for close contacts, such as household members or office colleagues, and is not designed for general prevention before attending events or traveling. Pharmaceutical companies are also developing other preventative measures, like nasal sprays.

Xocova functions as a protease inhibitor, a class of medication with extensive use in treating viral infections. Potential mild side effects include gastrointestinal upset, congestion, and muscle aches, which are generally considered preferable to COVID-19 symptoms.

The medication is prescribed for a short, five-day course. However, its high retail price of up to $1,400 without insurance could limit accessibility, though efforts are underway to ensure availability through various insurance plans and assistance programs.

Health officials emphasize that Xocova is an additional prevention tool and not a replacement for the COVID-19 vaccine. Vaccination remains the primary method of protection, especially for high-risk individuals, with continued adherence to public health precautions like mask-wearing and hand hygiene still recommended.